Replies to post #116872 on Biotech Values

[BTH]

Are there any good sell-side analysts? (I'm being somewhat serious).

My experience is the smaller-shops are the places to go to for unbiased research. And when I say 'smaller shops', I mean, small.

[efar]

Not aware of the situation with Pluristem, that does sound pretty slimy, but it looks like he initiated coverage of PSTI last year when the stock was at 1.20 and today it is more than double that at 2.50.

Also, in the Best on the Street survey released by the WSJ last year Vaino was the #1 ranked pharmaceutical analyst and The Financial Times ranked him #2 for biotech. As analysts go, I still think he is one of the more accurate...

As far as financing, I agree CYTK will need financing at some point. Right now it looks like they have enough cash to last ~4 quarters so a raise is likely in the next 9 months IMO.